Company Overview

SINTX Technologies, Inc. is a U.S.-based advanced materials company focused on the development and commercialization of silicon nitride–based ceramics. The company operates at the intersection of advanced ceramics, medical technology, and industrial materials, leveraging proprietary expertise in silicon nitride chemistry, processing, and intellectual property. Its core value proposition is the unique performance characteristics of silicon nitride, including high strength, thermal stability, wear resistance, and documented antimicrobial properties.

Historically, the company generated revenue through medical implant manufacturing, particularly spinal implants, but has since evolved its strategy toward licensing, materials development, and industrial and defense-adjacent applications. Originally founded in 1996 under the name Amedica Corporation, the company rebranded to SINTX Technologies, Inc. in 2018 to reflect a broader focus beyond medical devices and a strategic pivot toward diversified advanced ceramics markets.

Business Operations

SINTX Technologies conducts operations primarily through its core advanced ceramics platform, which encompasses materials research, intellectual property licensing, and limited manufacturing and prototyping. The company’s business activities are generally categorized into Advanced Ceramics and Medical Technology–related intellectual property, with current revenue largely derived from technology licensing, research agreements, and development partnerships rather than high-volume product sales.

Operations are primarily domestic, with U.S.-based research, engineering, and administrative functions. The company controls a portfolio of silicon nitride–related patents and trade secrets covering material composition, processing methods, and biomedical applications. While SINTX no longer operates large-scale medical device manufacturing, it maintains collaborations with external manufacturers, research institutions, and commercial partners to advance applications of its materials technology.

Strategic Position & Investments

Strategically, SINTX Technologies is focused on monetizing its silicon nitride platform through licensing agreements, joint development programs, and selective internal R&D. Growth initiatives emphasize non-traditional medical markets, including aerospace, defense, energy, and industrial wear components, where high-performance ceramics offer advantages over metals and polymers.

The company has made targeted investments in research programs exploring silicon nitride applications in armor, nuclear energy systems, and high-temperature industrial environments. Rather than pursuing large acquisitions, SINTX’s strategy centers on capital-efficient partnerships and the expansion of its patent portfolio. Information on specific portfolio companies or material equity investments is limited, and public disclosures indicate that strategic activity is primarily organic and partnership-driven; data on additional investments is inconclusive based on available public sources.

Geographic Footprint

SINTX Technologies is headquartered in North America, with its principal executive offices and operations located in Salt Lake City, Utah. The company’s operational footprint is primarily U.S.-based, reflecting its emphasis on research, intellectual property management, and domestic partnerships.

Internationally, SINTX maintains a market presence through licensing discussions, research collaborations, and historical product distribution in Europe and Asia, particularly in regions with established medical device and advanced manufacturing industries. While the company does not report extensive overseas facilities, its intellectual property portfolio is designed for global applicability, enabling international commercialization through partners.

Leadership & Governance

SINTX Technologies was originally founded by Aaron Hofmann and Scott Schaffner, whose early work established the company’s foundation in silicon nitride biomaterials. Current leadership emphasizes disciplined capital management, intellectual property monetization, and diversification beyond traditional medical devices.

Key members of leadership include:

• Eric K. Olson – President and Chief Executive Officer
• Todd M. Winn – Chief Financial Officer (title and tenure subject to change; data inconclusive based on recent public disclosures)
• Mark A. Stibich – Board Member and Executive Advisor (executive operational role not consistently disclosed)

The company’s governance and leadership philosophy centers on leveraging core materials science capabilities to access multiple end markets while reducing reliance on capital-intensive manufacturing models.